Cell cycle-dependent localization of the proteasome to chromatin.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 04 2020
02 04 2020
Historique:
received:
14
11
2019
accepted:
12
03
2020
entrez:
4
4
2020
pubmed:
4
4
2020
medline:
25
11
2020
Statut:
epublish
Résumé
An integrative understanding of nuclear events including transcription in normal and cancer cells requires comprehensive and quantitative measurement of protein dynamics that underlie such events. However, the low abundance of most nuclear proteins hampers their detailed functional characterization. We have now comprehensively quantified the abundance of nuclear proteins with the use of proteomics approaches in both normal and transformed human diploid fibroblasts. We found that subunits of the 26S proteasome complex were markedly down-regulated in the nuclear fraction of the transformed cells compared with that of the wild-type cells. The intranuclear proteasome abundance appeared to be inversely related to the rate of cell cycle progression, with restraint of the cell cycle being associated with an increase in the amount of proteasome subunits in the nucleus, suggesting that the nuclear proteasome content is dependent on the cell cycle. Furthermore, chromatin enrichment for proteomics (ChEP) analysis revealed enrichment of the proteasome in the chromatin fraction of quiescent cells and its apparent dissociation from chromatin in transformed cells. Our results thus suggest that translocation of the nuclear proteasome to chromatin may play an important role in control of the cell cycle and oncogenesis through regulation of chromatin-associated transcription factors.
Identifiants
pubmed: 32242037
doi: 10.1038/s41598-020-62697-2
pii: 10.1038/s41598-020-62697-2
pmc: PMC7118148
doi:
Substances chimiques
Chromatin
0
Proteome
0
Proteasome Endopeptidase Complex
EC 3.4.25.1
ATP dependent 26S protease
EC 3.4.99.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5801Références
Simicevic, J. & Deplancke, B. Transcription factor proteomics - Tools, applications, and challenges. Proteomics 17 (2017).
Gerstein, M. B. et al. Architecture of the human regulatory network derived from ENCODE data. Nature 489, 91–100 (2012).
doi: 10.1038/nature11245
pubmed: 22955619
pmcid: 22955619
Ernst, J. et al. Genome-scale high-resolution mapping of activating and repressive nucleotides in regulatory regions. Nat. Biotechnol. 34, 1180–1190 (2016).
doi: 10.1038/nbt.3678
pubmed: 27701403
pmcid: 27701403
Landry, C. R., Levy, E. D., Abd Rabbo, D., Tarassov, K. & Michnick, S. W. Extracting insight from noisy cellular networks. Cell 155, 983–989 (2013).
doi: 10.1016/j.cell.2013.11.003
pubmed: 24267884
pmcid: 24267884
Kustatscher, G., Wills, K. L., Furlan, C. & Rappsilber, J. Chromatin enrichment for proteomics. Nat. Protoc. 9, 2090–2099 (2014).
doi: 10.1038/nprot.2014.142
pubmed: 25101823
pmcid: 25101823
Ding, C. et al. Proteome-wide profiling of activated transcription factors with a concatenated tandem array of transcription factor response elements. Proc. Natl. Acad. Sci. USA 110, 6771–6776 (2013).
doi: 10.1073/pnas.1217657110
pubmed: 23553833
pmcid: 23553833
Hershko, A. Ubiquitin: roles in protein modification and breakdown. Cell 34, 11–12 (1983).
doi: 10.1016/0092-8674(83)90131-9
pubmed: 6309404
pmcid: 6309404
Nakayama, K. I. & Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6, 369–381 (2006).
doi: 10.1038/nrc1881
pubmed: 16633365
pmcid: 16633365
Muratani, M. & Tansey, W. P. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell Biol. 4, 192–201 (2003).
doi: 10.1038/nrm1049
pubmed: 12612638
pmcid: 12612638
McCann, T. S. & Tansey, W. P. Functions of the proteasome on chromatin. Biomolecules 4, 1026–1044 (2014).
doi: 10.3390/biom4041026
pubmed: 25422899
pmcid: 25422899
Epanchintsev, A. et al. Cockayne’s syndrome A and B proteins regulate transcription arrest after genotoxic stress by promoting ATF3 degradation. Mol. Cell 68, 1054–1066 (2017).
doi: 10.1016/j.molcel.2017.11.009
pubmed: 29225035
pmcid: 29225035
Pack, C. G. et al. Quantitative live-cell imaging reveals spatio-temporal dynamics and cytoplasmic assembly of the 26S proteasome. Nat. Commun. 5, 3396 (2014).
doi: 10.1038/ncomms4396
pubmed: 24598877
pmcid: 24598877
Enenkel, C. Proteasome dynamics. BBA-Mol. Cell Res. 1843, 39–46 (2014).
Wendler, P. & Enenkel, C. Nuclear transport of yeast proteasomes. Front. Mol. Biosci. 6, 6–34 (2019).
doi: 10.3389/fmolb.2019.00034
Chowdhury, M. & Enenkel, C. Intracellular Dynamics of the ubiquitin-proteasome-system. F1000Res. 4, 367 (2015).
doi: 10.12688/f1000research.6835.1
pubmed: 26339477
pmcid: 26339477
Matsumoto, M. et al. A large-scale targeted proteomics assay resource based on an in vitro human proteome. Nat. Methods 14, 251–258 (2017).
doi: 10.1038/nmeth.4116
pubmed: 28267743
pmcid: 28267743
Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
doi: 10.1093/nar/28.1.27
pubmed: 10592173
pmcid: 10592173
Meng, L. et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA 96, 10403–10408 (1999).
doi: 10.1073/pnas.96.18.10403
pubmed: 10468620
pmcid: 10468620
Schwarz, K. et al. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J. Immunol. 164, 6147–6157 (2000).
doi: 10.4049/jimmunol.164.12.6147
pubmed: 10843664
pmcid: 10843664
Fanning, E. & Knippers, R. Structure and Function of Simian Virus-40 Large Tumor-Antigen. Annu. Rev. Biochem. 61, 55–85 (1992).
doi: 10.1146/annurev.bi.61.070192.000415
Land, H., Parada, L. F. & Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596–602 (1983).
doi: 10.1038/304596a0
Danielsson, F. et al. Majority of differentially expressed genes are down-regulated during malignant transformation in a four-stage model. Proc. Natl. Acad. Sci. USA 112, 6853–6858 (2015).
doi: 10.1073/pnas.1511308112
Ahuja, D., Saenz-Robles, M. T. & Pipas, J. M. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24, 7729–7745 (2005).
doi: 10.1038/sj.onc.1209046
Yang, S. I. et al. Control of protein phosphatase 2A by simian virus 40 small-t antigen. Mol. Cell. Biol. 11, 1988–1995 (1991).
doi: 10.1128/MCB.11.4.1988
pubmed: 359884
pmcid: 359884
Manfredi, J. J. & Prives, C. The Transforming Activity of Simian-Virus-40 Large Tumor-Antigen. Bba-Rev. Cancer 1198, 65–83 (1994).
Wang, R. X. W., MacDuffie, E. & Santaguida, S. Generation and isolation of cell cycle-arrested cells with complex karyotypes. Jove-J. Vis. Exp. 134 (2018).
Rodier, G. et al. p107 inhibits G1 to S phase progression by downregulating expression of the F-box protein Skp2. J. Cell Biol. 168, 55–66 (2005).
doi: 10.1083/jcb.200404146
pubmed: 2171673
pmcid: 2171673
Gingras, A. C., Aebersold, R. & Raught, B. Advances in protein complex analysis using mass spectrometry. J. Physiol-London 563, 11–21 (2005).
doi: 10.1113/jphysiol.2004.080440
Ee, G. & Lehming, N. How the ubiquitin proteasome system regulates the regulators of transcription. Transcription 3, 235–239 (2012).
doi: 10.4161/trns.21249
pubmed: 3632619
pmcid: 3632619
Zhu, Q. et al. The ubiquitin-proteasome system regulates p53-mediated transcription at p21
doi: 10.1038/sj.onc.1210191
Burcoglu, J., Zhao, L. & Enenkel, C. Nuclear import of yeast proteasomes. Cells 4, 387–405 (2015).
doi: 10.3390/cells4030387
pubmed: 4588042
pmcid: 4588042
Laporte, D., Salin, B., Daignan-Fornier, B. & Sagot, I. Reversible cytoplasmic localization of the proteasome in quiescent yeast cells. J. Cell. Biol. 181, 737–745 (2008).
doi: 10.1083/jcb.200711154
pubmed: 2396804
pmcid: 2396804
Peters, L. Z., Karmon, O., Miodownik, S. & Ben-Aroya, S. Proteasome storage granules are transiently associated with the insoluble protein deposit in Saccharomyces cerevisiae. J. Cell. Sci. 129, 1190–1197 (2016).
doi: 10.1242/jcs.179648
Nalley, K., Johnston, S. A. & Kodadek, T. Proteolytic turnover of the Gal4 transcription factor is not required for function in vivo. Nature 442, 1054–1057 (2006).
doi: 10.1038/nature05067
pubmed: 16929306
pmcid: 16929306
Collins, G. A., Lipford, J. R., Deshaies, R. J. & Tansey, W. P. Gal4 turnover and transcription activation. Nature 461 (2009).
Kume, K. et al. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell 98, 193–205 (1999).
doi: 10.1016/S0092-8674(00)81014-4
Shearman, L. P. et al. Interacting molecular loops in the mammalian circadian clock. Science 288, 1013–1019 (2000).
doi: 10.1126/science.288.5468.1013
Strikoudis, A., Guillamot, M. & Aifantis, I. Regulation of stem cell function by protein ubiquitylation. EMBO Rep. 15, 365–382 (2014).
doi: 10.1002/embr.201338373
pubmed: 24652853
pmcid: 24652853
Mohammad, K., Dakik, P., Medkour, Y., Mitrofanova, D. & Titorenko, V. I. Quiescence entry, maintenance, and exit in adult stem cells. Int. J. Mol. Sci. 20 (2019).
Yada, M. et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23, 2116–2125 (2004).
doi: 10.1038/sj.emboj.7600217
pubmed: 15103331
pmcid: 15103331
Matsuoka, S. et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 22, 986–991 (2008).
doi: 10.1101/gad.1621808
pubmed: 18367647
pmcid: 18367647
Takeishi, S. et al. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell. 23, 347–361 (2013).
doi: 10.1016/j.ccr.2013.01.026
pubmed: 23518349
pmcid: 23518349
Inuzuka, H. et al. SCF
doi: 10.1038/nature09732
pubmed: 21368833
pmcid: 21368833
Jiang, H. et al. Ubiquitylation of RAG-2 by Skp2-SCF links destruction of the V(D)J recombinase to the cell cycle. Mol. Cell. 18, 699–709 (2005).
doi: 10.1016/j.molcel.2005.05.011
pubmed: 15949444
pmcid: 15949444
Nielsen, S. V., Poulsen, E. G., Rebula, C. A. & Hartmann-Petersen, R. Protein quality control in the nucleus. Biomolecules 4, 646–661 (2014).
doi: 10.3390/biom4030646
pubmed: 25010148
pmcid: 25010148
Enam, C., Geffen, Y., Ravid, T. & Gardner, R. G. Protein quality control degradation in the nucleus. Annu. Rev. Biochem. 87, 725–749 (2018).
doi: 10.1146/annurev-biochem-062917-012730
pubmed: 29925261
pmcid: 29925261
Moser, J., Miller, I., Carter, D. & Spencer, S. L. Control of the restriction point by Rb and p21. Proc. Natl. Acad. Sci. USA 115, Eb219–Eb227 (2018).
doi: 10.1073/pnas.1804179115
Pardee, A. B. A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci. USA 71, 1286–1290 (1974).
doi: 10.1073/pnas.71.4.1286
pubmed: 4524638
pmcid: 4524638
Foster, D. A., Yellen, P., Xu, L. & Saqcena, M. Regulation of G1 cell cycle progression: Distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s). Genes Cancer 1, 1124–1131 (2010).
doi: 10.1177/1947601910392989
pubmed: 21779436
pmcid: 21779436
Yang, H. W., Chung, M., Kudo, T. & Meyer, T. Competing memories of mitogen and p53 signalling control cell-cycle entry. Nature 549, 404–408 (2017).
doi: 10.1038/nature23880
pubmed: 6544019
pmcid: 6544019
Kanayama, H. et al. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res. 51, 6677–6685 (1991).
pubmed: 1660345
pmcid: 1660345
Tsvetkov, P. et al. Oncogenic addiction to high 26S proteasome level. Cell Death Dis. 9, 773 (2018).
doi: 10.1038/s41419-018-0806-4
pubmed: 29991718
pmcid: 29991718
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
doi: 10.1038/nature12634
pubmed: 24132290
pmcid: 24132290
Muller, P. A. J. & Vousden, K. H. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities. Cancer Cell 25, 304–317 (2014).
doi: 10.1016/j.ccr.2014.01.021
pubmed: 24651012
pmcid: 24651012
Maddison, L. A., Sutherland, B. W., Barrios, R. J. & Greenberg, N. M. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res. 64, 6018–6025 (2004).
doi: 10.1158/0008-5472.CAN-03-2509
pubmed: 15342382
pmcid: 15342382
Oshikawa, K., Matsumoto, M., Oyamada, K. & Nakayama, K. I. Proteome-wide Identification of Ubiquitylation Sites by Conjugation of Engineered Lysine-less Ubiquitin. J. Proteome Res. 11, 796–807 (2012).
doi: 10.1021/pr200668y
pubmed: 22053931
pmcid: 22053931
Nakatsumi, H., Oka, T., Higa, T., Shirane, M. & Nakayama, K. I. Nuclear-cytoplasmic shuttling protein PP2A(B56) contributes to mTORC1-dependent dephosphorylation of FOXK1. Genes Cells 23, 599–605 (2018).
doi: 10.1111/gtc.12597
pubmed: 29845697
pmcid: 29845697
Hatakeyama, S., Watanabe, M., Fujii, Y. & Nakayama, K. I. Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation. Cancer Res. 65, 7874–7879 (2005).
doi: 10.1158/0008-5472.CAN-05-1581
pubmed: 16140957
pmcid: 16140957
Schwanhausser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337–342 (2011).
doi: 10.1038/nature10098
pubmed: 21593866
pmcid: 21593866
Matic, I. et al. Absolute SILAC-compatible expression strain allows Sumo-2 copy number determination in clinical samples. J. Proteome Res. 10, 4869–4875 (2011).
doi: 10.1021/pr2004715
pubmed: 3189705
pmcid: 3189705
Foster, J. S., Fernando, R. I., Ishida, N., Nakayama, K. I. & Wimalasena, J. Estrogens down-regulate p27
doi: 10.1074/jbc.M302830200
Sugiyama, S., Yumimoto, K., Inoue, I. & Nakayama, K. I. SCF(Fbxw7) ubiquitylates KLF7 for degradation in a manner dependent on GSK-3-mediated phosphorylation. Genes Cells 24, 354–365 (2019).
doi: 10.1111/gtc.12680
Katayama, Y. et al. CHD8 haploinsufficiency results in autistic-like phenotypes in mice. Nature 537, 675–679 (2016).
doi: 10.1038/nature19357
Minamishima, Y. A., Nakayama, K. & Nakayama, K. I. Recovery of liver mass without proliferation of hepatocytes after partial hepatectomy in skp2-deficient mice. Cancer Res. 62, 995–999 (2002).
Matsuzaki, F., Shirane, M., Matsumoto, M. & Nakayama, K. I. Protrudin serves as an adaptor molecule that connects KIF5 and its cargoes in vesicular transport during process formation. Mol. Biol. Cell 22, 4602–4620 (2011).
doi: 10.1091/mbc.e11-01-0068
pubmed: 3226478
pmcid: 3226478
Nagahama, H. et al. Spatial and temporal expression patterns of the cyclin-dependent kinase (CDK) inhibitors p27
doi: 10.1007/s004290000146
Takahashi, H., Hatakeyama, S., Saitoh, H. & Nakayama, K. I. Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein. J. Biol. Chem. 280, 5611–5621 (2005).
doi: 10.1074/jbc.M408130200
Vilchez, D. et al. Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature 489, 304–308 (2012).
doi: 10.1038/nature11468
pubmed: 5215918
pmcid: 5215918
Nakayama, K. et al. Impaired degradation of inhibitory subunit of NF-κB (IκB) and β-catenin as a result of targeted disruption of the β-TrCP1 gene. Proc. Natl. Acad. Sci. USA 100, 8752–8757 (2003).
doi: 10.1073/pnas.1133216100
Becher, I. et al. Pervasive protein thermal stability variation during the cell cycle. Cell 173, 1495–1507 (2018).
doi: 10.1016/j.cell.2018.03.053
pubmed: 29706546
pmcid: 29706546
Beauchemin, M. & Morse, D. A proteomic portrait of dinoflagellate chromatin reveals abundant RNA-binding proteins. Chromosoma 127, 29–43 (2018).
doi: 10.1007/s00412-017-0643-8
Matsumoto, A., Takeishi, S. & Nakayama, K. I. p57 regulates T-cell development and prevents lymphomagenesis by balancing p53 activity and pre-TCR signaling. Blood 123, 3429–3439 (2014).
doi: 10.1182/blood-2013-10-532390
Imaki, H. et al. Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein. Cancer Res. 63, 4607–4613 (2003).
Parcellier, A. et al. HSP27 favors ubiquitination and proteasomal degradation of p27
doi: 10.1096/fj.05-4184fje